Two-Part, Open-Label Study to Evaluate Single Dose Pharmacokinetics of an Obefazimod Minitablet Formulation, Estimate the Relative Bioavailability of the Minitablet Formulation and to Evaluate Minitablet Palatability in Healthy Participants

The sponsor is developing a pediatric minitablet formulation as part of the overall pharmaceutical development strategy. In vitro dissolution and physiological-based bio-pharmaceutics modelling and simulation have been used to guide the development of the mini-tablet formulation to match the PK exposure of the adult capsule formulation. The study aims to investigate the relative bioavailability of the 50mg minitablet compared to the adult obefazimod 50 mg capsule in adult healthy volunteers.

Start Date01 Mar 2026

Sponsor / Collaborator

Abivax SA

[+1]

NCT06456593

/ RecruitingPhase 2

A Phase 2b, Multicenter, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Obefazimod in Subjects With Moderately to Severely Active Crohn's Disease

This study has 3 treatment phases, a 12-Week Induction Phase, a 40-Week Maintenance Phase, and a 48-Week Extension Phase.
The objective is to evaluate the efficacy and safety of obefazimod compared to placebo as induction and maintenance therapy in subjects with moderately to severely active CD after inadequate response (no response, loss of response, or intolerance) to conventional therapies and/or advanced therapies.
The primary objective for the 48-Week Extension Phase is to evaluate the safety and tolerability of obefazimod compared with placebo in subjects who are enrolled in the Extension Phase.

Start Date30 Oct 2024

Sponsor / Collaborator

Abivax SA

CTIS2024-514561-20-00

/ CompletedPhase 1

A Phase I study to evaluate the pharmacokinetics, safety and tolerability of multiple oral doses of obefazimod in participants with renal impairment and matched normal kidney function.

Start Date09 Sep 2024

Sponsor / Collaborator

Abivax SA

100 Clinical Results associated with Obefazimod

100 Translational Medicine associated with Obefazimod

100 Patents (Medical) associated with Obefazimod

Literatures (Medical) associated with Obefazimod

01 Nov 2024·JOURNAL OF CATALYSIS

Air-stable, well-defined palladium–BIAN–NHC chloro dimer: Highly efficient N-Heterocyclic carbene (NHC) catalyst platform for Buchwald–Hartwig C–N cross-coupling reactions

Author: Szostak, Michal ; Yan, Wenxuan ; Li, Xue ; Tong, Jianbo ; Zhang, Jin ; Zhang, Gaopeng ; Cai, Jianglong ; Li, Renjie

Buchwald-Hartwig amination has become the fundamental method for constructing mol. architectures throughout chem. research, including the synthesis of pharmaceutical agents, natural products, fine chems., and advanced materials.Herein, we report air-stable, well-defined palladium-BIAN-NHC chloro dimer, [Pd(BIAN-NHC)(μ-Cl)Cl]₂, for Buchwald-Hartwig C-N cross-coupling reactions of aryl halides.This rapidly activating catalyst framework merges the reactive properties of palladium chloro dimers, [Pd(NHC)(μ-Cl)Cl]₂, with the structural features of acenaphthoimidazol-2-ylidenes.[Pd(BIAN-NHC)(μ-Cl)Cl]₂ is the most reactive Pd(II)-NHC precatalyst to date, undergoing fast activation under both inert atm. and aerobic conditions.The catalyst shows an excellent reactivity in Buchwald-Hartwig amination of aryl halides (59 examples), including challenging substrates, diamination and direct functionalization of pharmaceuticals.The steric protection enables high reactivity under both inert atm. and aerobic conditions.[Pd(BIAN-IPr)(μ-Cl)Cl]₂ should be routinely utilized for the synthesis of C-N bonds to make valuable amines, where it replaces the most commonly deployed at present IPr (IPr = 1,3-bis(2,6-isopropyl)imidazol-2-ylidene).

01 Sep 2024·BIOORGANIC & MEDICINAL CHEMISTRY

Current status of the small molecule anti-HIV drugs in the pipeline or recently approved

Review

Author: Katandula, Jonathan ; Twizeyimana, Eric ; Uyisenga, Jeanne Primitive ; Nyandwi, Jean Baptiste ; Saeed, Shamsaldeen Ibrahim ; Ishimwe, Nestor ; Umumararungu, Théoneste ; Claude Tomani, Jean ; Olawode, Emmanuel Oladayo ; Gahamanyi, Noël ; Habarurema, Gratien ; Mpenda, Matabishi

Human Immunodeficiency Virus (HIV) is the causative agent of Acquired Immunodeficiency Syndrome (AIDS) with high morbidity and mortality rates. Treatment of AIDS/HIV is being complicated by increasing resistance to currently used antiretroviral (ARV) drugs, mainly in low- and middle-income countries (LMICs) due to drug misuse, poor drug supply and poor treatment monitoring. However, progress has been made in the development of new ARV drugs, targeting different HIV components (Fig. 1). This review aims at presenting and discussing the progress made towards the discovery of new ARVs that are at different stages of clinical trials as of July 2024. For each compound, the mechanism of action, target biomolecule, genes associated with resistance, efficacy and safety, class, and phase of clinical trial are discussed. These compounds include analogues of nucleoside reverse transcriptase inhibitors (NRTIs) - islatravir and censavudine; non-nucleoside reverse transcriptase inhibitors (NNRTIs) - Rilpivirine, elsulfavirine and doravirine; integrase inhibitors namely cabotegravir and dolutegravir and chemokine coreceptors 5 and 2 (CC5/CCR2) antagonists for example cenicriviroc. Also, fostemsavir is being developed as an attachment inhibitor while lenacapavir, VH4004280 and VH4011499 are capsid inhibitors. Others are maturation inhibitors such as GSK-254, GSK3532795, GSK3739937, GSK2838232, and other compounds labelled as miscellaneous (do not belong to the classical groups of anti-HIV drugs or to the newer classes) such as obefazimod and BIT225. There is a considerable progress in the development of new anti-HIV drugs and the effort will continue since HIV infections has no cure or vaccine till now. Efforts are needed to reduce the toxicity of available drugs or discover new drugs with new classes which can delay the development of resistance.

01 Apr 2024·International journal for parasitology. Drugs and drug resistance

Structure-activity relationship and target investigation of 2-aryl quinolines with nematocidal activity

Article

Author: Harrison T. Shanley ; Aya C. Taki ; Cécile Häberli ; Robin B. Gasser ; Nghi Nguyen ; Neil D. Young ; Brad E. Sleebs ; Jennifer Keiser ; Andreas Hofmann ; Yuanting Zheng ; Nicholas Williamson ; Shuai Nie ; Tim N.C. Wells ; Bill C.H. Chang ; Michael G. Leeming ; Abdul Jabbar ; Pasi K. Korhonen ; Joseph J. Byrne ; Ching-Seng Ang ; Tao Wang

Within the context of our anthelmintic discovery program, we recently identified and evaluated a quinoline derivative, called ABX464 or obefazimod, as a nematocidal candidate; synthesised a series of analogues which were assessed for activity against the free-living nematode Caenorhabditis elegans; and predicted compound-target relationships by thermal proteome profiling (TPP) and in silico docking. Here, we logically extended this work and critically evaluated the anthelmintic activity of ABX464 analogues on Haemonchus contortus (barber's pole worm) - a highly pathogenic nematode of ruminant livestock. First, we tested a series of 44 analogues on H. contortus (larvae and adults) to investigate the nematocidal pharmacophore of ABX464, and identified one compound with greater potency than the parent compound and showed moderate activity against a select number of other parasitic nematodes (including Ancylostoma, Heligmosomoides and Strongyloides species). Using TPP and in silico modelling studies, we predicted protein HCON_00074590 (a predicted aldo-keto reductase) as a target candidate for ABX464 in H. contortus. Future work aims to optimise this compound as a nematocidal candidate and investigate its pharmacokinetic properties. Overall, this study presents a first step toward the development of a new nematocide.

118

News (Medical) associated with Obefazimod

01 Apr 2026

·ir.abivax.com

Abivax Publishes Financial Reports with the French and U.S. Securities Regulatory Agencies

Abivax publishes financial reports with the French and U.S. securities regulatory agencies PARIS, France – April 1, 2026 – 10:05 PM CEST – Abivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, announces the filing of its Universal Registration Document (Document d’Enregistrement Universel) with the French Financial Market Authorities, Autorité des Marchés Financiers (AMF), and the filing of its Annual Report (20-F) with the U.S. Securities and Exchange Commission (SEC) on March 23, 2026. The Universal Registration Document includes the 2025 annual financial report, the management report including the report on corporate governance, as well as the reports of the statutory auditors. The documents will be available for download on the website of Abivax (www.abivax.com/investors), the AMF (www.amf-france.org), and the SEC (www.sec.gov/edgar). About Abivax Abivax is a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Based in France and the United States, Abivax’s lead drug candidate, obefazimod (ABX464), is in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis. Contact: Patrick Malloy SVP, Investor Relations Abivax SA patrick.malloy@abivax.com +1 847 987 4878 Attachment 2026_04_01_Abivax Publishes Financial Reports with Regulatory Agencies

Phase 3

27 Mar 2026

·endpoints.news

Recursion appoints former Exelixis CMO; More executive moves at Incyte

→ Recursion has hired a new top doctor, bringing on Vicki Goodman as chief medical officer. Goodman previously served as CMO of the cancer biotechs Exelixis and Mural Oncology . She is taking over for David Mauro , who has been in the role for nearly three years. Goodman’s hiring is one of the biggest executive changes since Najat Khan took over as CEO at the start of 2026. → Pablo Cagnoni ’s job title at Incyte has been modified to president and global head of R&D, while longtime CMO Steven Stein will add to his responsibilities as head of late-stage development. CEO Bill Meury wasn’t done, naming J&J vet Mohamed Issa as head of US commercial. Issa had led the US oncology business and that won’t change with this role, but his leadership will extend to US immunology as well. Finally, Matteo Trotta — who came to Incyte in 2024 after 12 years at Novartis — is stepping down as US general manager, dermatology. Incyte has passed through Peer Review frequently since August, hiring a chief strategy officer, HR chief and general counsel. → Emil deGoma is a first-time CMO at Braveheart Bio , a new cardio bet that raised a $185 million Series A in November after doing a deal with Hengrui . The Akebia vet was SVP of medical research at Tourmaline Bio , which Novartis bought last year to boost a heart disease pipeline that already includes its blockbuster Entresto . “His background as an academic cardiologist and his industry experience advancing innovative medicines position him well to guide our clinical programs,” Braveheart CEO Travis Murdoch said in a statement. Murdoch sold HI-Bio to Biogen in 2024, and Braveheart is now chaired by Biogen CEO Chris Viehbacher . → David Marek quietly stepped down as CEO of ReAlta Life Sciences in October, according to his LinkedIn, and the Virginia-based biotech has tapped chairman Howard Berman as his successor. This is Berman’s first CEO appointment since he led Coya Therapeutics from 2020-24, and he has chaired the board at ReAlta since November. One more note: Madrigal Pharmaceuticals alum and ReAlta board member Kia Motesharei has been named president and COO. He had a short stint as an entrepreneur-in-residence at Formation Bio after more than two years with Madrigal as SVP, business & corporate development. → On March 30, Jennifer Jarrett will be president and CEO of Damora Therapeutics , which was purchased by Galecto and will carry on under the Damora name. Fairmount Funds founding partner Peter Harwin will chair the board, while Spyre Therapeutics CEO Cameron Turtle and ex- Blueprint Medicines finance chief Mike Landsittel are the newest board members. Jarrett had been a key member of the team at Arcus Biosciences in two separate stints since 2017, including the last five-plus years as COO. From 2019-20, she was head of corporate development and capital markets for Uber . You can also find her on the board of directors at Sagimet Biosciences , Syndax Pharmaceuticals and Zura Bio . → There’s a changing of the guard at Basel-based Anaveon . Andreas Katopodis is handing the CEO keys to Thaminda Ramanayake , who was recently chief business officer at CureVac , the mRNA biotech that he helped merge with rival BioNTech . Ramanayake is also a venture partner at the investment fund Entrée Bioventures . Anaveon is working on depleting pathogenic T cells for autoimmune diseases and inflammatory disorders. The company used to be clinical-stage with its initial goal of joining the IL-2 race , but that mission appears to have ended . Anaveon said it is backed by Syncona , Forbion , Blue Owl , Pontifax and the venture arms of Novartis and Pfizer . Anaveon’s chair is former Bayer CEO Dieter Weinand . → Two key execs have made their way to Averna Therapeutics , one of last year’s Endpoints 11 winners : CSO Robert Mabry worked for Averna CEO Tom Barnes in the same capacity at Orna Therapeutics , and Mabry has also been global head of biologics for Takeda . And Richard Morris has another CFO assignment following stints at Carisma Therapeutics , Passage Bio and Context Therapeutics . Averna’s focus on “jumping genes” — also known as retrotransposons — has additional competition . → France’s Abivax turned an experimental HIV drug ( obefazimod ) into a much-anticipated inflammatory disease treatment. As it prepares to take obefazimod to regulators, it has hired nine-year Takeda veteran Michael Nesrallah as its new chief commercial officer. Nesrallah filled multiple roles during his Takeda tenure, including general manager of Belgium, franchise head for IBD, leader of commercial operations for the US specialty business, and more. Obefazimod’s clinical success thus far in ulcerative colitis has drummed up M&A rumors. Alongside Nesrallah, Abivax also named Keith Fournier as SVP of global regulatory affairs and Maurus de la Rosa as SVP of research. Meanwhile, Sofinnova Partners ’ Kinam Hong stepped down from the board on March 19. → Led by ex- Prevail CEO Asa Abeliovich , neuro upstart Leal Therapeutics has brought in Johannes Tauscher as CMO, according to the search firm that helped with the appointment. Tauscher completed a dozen years with Takeda last summer and was the Japanese pharma’s global head of imaging. Leal broke cover in August with a $30 million Series A and a schizophrenia candidate called LTX-001 . → ADARx Pharmaceuticals has hopped aboard the banker-to-CFO train. The RNA startup poached Goldman Sachs healthcare investment banker Ryan Fisk , who will be chief financial and business officer at the San Diego biotech. Multiple other private drug developers have hired bankers to lead finance and help them go public. ADARx is a likely IPO candidate, since it’s already in Phase 3 with a hot drug modality, pharma validity with a major AbbVie pact , and backing from blue-chip investors like Bain Capital and TCGX . Fisk wrote to his LinkedIn following that he believes ADARx can be a “generational biotech company.” → For the third time this month , Peer Review is bringing you news of a Royalty Pharma hire. This time, decade-long IQVIA veteran Lucas Glass is becoming Royalty’s head of AI. “By incorporating intelligent automation, advanced analytics and AI-driven decision support, we are strengthening how we evaluate and invest in royalties and support our partners,” CEO Pablo Legorreta said in a statement . Glass was most recently SVP of technology at IQVIA. → Rani Therapeutics has selected ex- Radius Health chief Jesper Høiland as head of strategy. Høiland spent three decades at Novo Nordisk , and when Kelly Martin succeeded him at Radius Health, he became global chief commercial officer at Ascendis Pharma . He retired from Ascendis in 2022. → Mineralys Therapeutics has recruited Jeffrey Munsie as chief legal officer. Munsie previously held this position at two biotechs that have been acquired: Orbital Therapeutics (bought by Bristol Myers Squibb ) and Concert Pharmaceuticals (bought by Sun Pharma ). Will Mineralys be added to the list? Its aldosterone synthase inhibitor lorundrostat is showing promise in hypertension and has a Dec. 22 decision date with the FDA. → Atacicept maker Vera Therapeutics also has a new legal chief. Jane Wright-Mitchell spent more than two years with Vaxcyte as general counsel, chief compliance officer and corporate secretary, and she’s also worked on the legal teams at Mesoblast and Purdue Pharma . The FDA set a July 7 PDUFA date for atacicept in patients with IgA nephropathy. → Jennifer McDonough is getting started at Palvella Therapeutics as SVP of market access and patient services. McDonough was on the crew behind the commercial launch of the gene therapy Vyjuvek as SVP, patient access, analytics & operations at fellow Pennsylvania drugmaker Krystal Biotech . → Endpoints 11 winner Umoja Biopharma has welcomed Avenzo Therapeutics CEO Athena Countouriotis to the board of directors, along with Massachusetts General Hospital’s Marcela Maus . Countouriotis ran Turning Point Therapeutics until Bristol Myers scooped it up in 2022, and she’s also a board member at BioMarin , Iovance and Recludix Pharma , among others. → CAMP4 Therapeutics has elected Michael MacLean to the board of directors. MacLean is mapping out his next chapter after nearly six years as CFO of Avidity Biosciences , the RNA specialist that was sold to Novartis for $12 billion. → After retiring from Morgan Stanley in February, Jessica Chutter has joined the board of directors at PTC Therapeutics . Chutter had a 40-year career with Morgan Stanley, where she had been managing director and chair of biotechnology investment banking. Andrew Dunn also contributed to this edition.

Executive ChangeIPOAcquisition

24 Mar 2026

·www.fiercepharma.com

Abivax hires commercial chief from Takeda to infuse Entyvio expertise into IBD launch prep

Nesrallah will lead launch preparations and global commercial strategy at Abivax, which expects to report phase 3 data on its obefazimod in ulcerative colitis by mid-2026. Abivax has appointed Michael Nesrallah as its chief commercial officer, putting one of the people who turned Takeda’s Entyvio into a blockbuster in charge of preparations for its own ulcerative colitis launch.Paris-based Abivax expects to report phase 3 data on obefazimod in ulcerative colitis by mid-2026. With previous studies raising hopes for the small molecule, which selectively upregulates miR-124 in immune cells, the biotech has climbed up analysts’ lists of potential takeover targets. AstraZeneca and Eli Lilly have reportedly shown an interest in buying Abivax, which could command a fee of around $18 billion.Against that backdrop, Abivax is currently preparing to launch obefazimod itself. Nesrallah will lead the launch preparations and global commercial strategy as Abivax’s chief commercial officer, the company announced in its full-year 2025 earnings release Tuesday. Jefferies analysts interpreted the appointment as a positive for Abivax: “We view this as strong validation for obe’s launch potential,” the analysts wrote in a note to investors. “Some will debate what this may mean for strategic optionality. We don't think this matters as biotech companies always have to prepare for running their business as a standalone co[mpany]” Abivax’s new executive spent most of the last decade at Takeda, where he held multiple leadership roles, including U.S. franchise head for the Japanese drugmaker’s inflammatory bowel disease (IBD) business. Nesrallah’s responsibilities at Takeda included expanding access to the ulcerative colitis drug Entyvio and growing its sales, which most recently hit (PDF) 744.5 billion Japanese yen ($4.7 billion) in the first nine months of the company’s fiscal 2025. Entyvio, an anti-integrin antibody, is just one in a sea of IBD drugs. While the market is fiercely competitive, obefazimod’s mechanism sets it apart from approved and investigational therapies owned by companies including AbbVie, Bristol Myers Squibb, Johnson & Johnson, Lilly and Pfizer. By hiring Nesrallah, Abivax appears to be stepping up preparations to communicate the differences to patients and physicians, along with laying the broader groundwork for a potential launch.“Abivax is entering an exciting new chapter, and I’m thrilled to be joining the Company at such a pivotal moment,” Nesrallah said in a statement. “We have a meaningful opportunity ahead to further strengthen our commercial capabilities to prepare for the successful launch of obefazimod, if approved, which has the potential to truly make a difference for patients.”

Executive ChangePhase 3Acquisition

100 Deals associated with Obefazimod

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	-	DB14828

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Colitis, Ulcerative	Phase 3	Argentina	Abivax SA	10 Oct 2022
Colitis, Ulcerative	Phase 3	Australia	Abivax SA	10 Oct 2022
Colitis, Ulcerative	Phase 3	Austria	Abivax SA	10 Oct 2022
Colitis, Ulcerative	Phase 3	Bulgaria	Abivax SA	10 Oct 2022
Colitis, Ulcerative	Phase 3	Canada	Abivax SA	10 Oct 2022
Colitis, Ulcerative	Phase 3	Czechia	Abivax SA	10 Oct 2022
Colitis, Ulcerative	Phase 3	Greece	Abivax SA	10 Oct 2022
Colitis, Ulcerative	Phase 3	Hungary	Abivax SA	10 Oct 2022
Colitis, Ulcerative	Phase 3	India	Abivax SA	10 Oct 2022
Colitis, Ulcerative	Phase 3	Netherlands	Abivax SA	10 Oct 2022

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03760003 (CTgov)	Phase 2	Ulcerative proctitis \| Neoplasms \| Colitis, Ulcerative	355	ABX464 100 mg (ABX464 100 mg)	apthozxfzt(fxxjyqwjra) = kftzmkpvvw xhkrtetcpr (itnqdpsrco, rvnirdyndf - acrakkswpv) View more	-	28 Nov 2025
				ABX464 50 mg (ABX464 50 mg)	apthozxfzt(fxxjyqwjra) = cfvfdudoll xhkrtetcpr (itnqdpsrco, mxdsavlcqx - btqqreskzc) View more
NCT04393038 (Mir-Age, CTgov)	Phase 2/3	Respiratory Failure \| COVID-19 \| Inflammation	509	ABX464 (ABX464)	izkylwfucl = vkmgafnltp bhjaxjdrwe (krwayeasiu, dqrkbfhvya - tuiagqrghk) View more	-	26 Nov 2025
				Placebo (Placebo)	izkylwfucl = maypqodjqt bhjaxjdrwe (krwayeasiu, fvwjeahjtq - ctetdneneu) View more
NCT05507203 \| NCT05507216 (ABTECT-2, Company_Website 1 \| Company_Website 2) Manual	Phase 3	Colitis, Ulcerative Second line \| First line \| Last line	1,272	Placebo (ABTECT 1 & 2)	mvkfjkotxy(pqfvicikud) = 50 mg once-daily dose of obefazimod led to a pooled 16.4% (p<0.0001) placebo-adjusted clinical remission rate at Week 8. ewbfhfxxvn (vsfvdfwfjx ) Met View more	Positive	06 Oct 2025
				Obefazimod 25 mg (ABTECT 1 & 2)
NCT05507216 (ABTECT-2, Company_Website) Manual	Phase 3	Colitis, Ulcerative	636	ABX464 25 mg	qrcmxqrmxq(bamavgslte) = hhbwlqmzsl euxdzgdisb (lycfdhxlsn ) View more	Positive	22 Jul 2025
				ABX464 50 mg	qrcmxqrmxq(bamavgslte) = enxsoxqfbr euxdzgdisb (lycfdhxlsn ) View more
NCT05507203 (ABTECT-1, Company_Website) Manual	Phase 3	Colitis, Ulcerative	636	ABX464 25 mg	xpmecrklzl(fkkundvuwy) = wfflzwwfxu zewzdnahiq (ndwywbohze ) View more	Positive	22 Jul 2025
				ABX464 50 mg	xpmecrklzl(fkkundvuwy) = mnrlnikubv zewzdnahiq (ndwywbohze ) View more
NCT04023396 (Phase 2b study, Pubmed \| J Crohns Colitis)	Phase 2	Colitis, Ulcerative Maintenance miR-124	222	Obefazimod 25mg	wvgghewnjr(kcuevqogay) = 14.3% aatpdujznb (sljhobdsxc ) View more	Positive	26 May 2025
				Obefazimod 50mg
NCT04023396 (Phase 2b study \| phase 2b, CTgov)	Phase 2	Colitis, Ulcerative	217	ABX464	ooazhcarod = asimcfqgmq miggfhhfxs (vtswiltjwz, uyzzuylcwp - xrsrzsfbtr) View more	-	27 Apr 2025
NCT03368118 (CTgov)	Phase 2	Colitis, Ulcerative	22	ABX464	otqkumbvhp = uegbhnziaq bcgyzsdqfz (ifptlqyqhr, lamhtvcliq - ijqpdbbypf) View more	-	05 Mar 2025
UEGW2024	Not Applicable	-	-	Obefazimod 25mg	oclnneceji(splebaujpn) = bbhrurkjld gjwhuveioa (lwzdgwfyxo ) View more	-	13 Oct 2024
				Placebo	oclnneceji(splebaujpn) = wwxrdohyzq gjwhuveioa (lwzdgwfyxo ) View more
INDUCTION TRIAL (UEGW2024)	Phase 3	Ulcerative colitis, active moderate	252	Obefazimod 25mg	jwjvxuiezb(nvvknualey) = rweygsoype hnglgeywrl (bawfueptfa ) View more	Positive	13 Oct 2024
				Obefazimod 50mg	jwjvxuiezb(nvvknualey) = rejpikccnf hnglgeywrl (bawfueptfa ) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis